One dated view of what has been peer reviewed, what remains a sponsor topline report, and which detailed publications are still pending. Evidence state comes before headline magnitude.
Status, 2 November 2026: Lilly plans to submit retatrutide for US approval in the first quarter of 2027, according to its 23 July 2026 investor release. No submission had been filed when this tracker was reviewed.
Retatrutide remains investigational. This tracker is research context, not clinical or personal-use guidance.
The statuses below describe the source available for each result, not an approval status or a judgment about clinical use.
Adults with type 2 diabetes inadequately controlled by diet and exercise · Phase 3 · 40 weeks
The randomized double-blind trial was published in The Lancet. The published abstract reports mean body-weight changes of −11.5%, −13.9% and −15.3% for the 4 mg, 9 mg and 12 mg groups, compared with −2.6% for placebo. The trial record lists 537 participants and NCT06354660.
Adults with obesity or overweight without diabetes · Phase 3 · 80-week primary analysis
The full results were published in The New England Journal of Medicine on 29 September 2026. The paper reports a 25.0% mean body-weight reduction in the 12 mg arm under the treatment-regimen estimand at 80 weeks. Lilly’s 21 May 2026 topline reported up to 28.3% under the efficacy estimand; the two figures answer different questions and are not a correction of each other.
Adults with obesity or overweight and type 2 diabetes · Phase 3 · 80 weeks
The full results were presented at the EASD 2026 meeting and published in The Lancet (Bellido et al.). In 1,152 randomised adults, mean body-weight change at week 80 was −11.9%, −16.8% and −18.8% for the 4 mg, 9 mg and 12 mg groups, compared with −5.1% for placebo, under the treatment-regimen estimand. Lilly’s 23 July 2026 topline reported up to 20.8% (12 mg) and up to a 1.6% A1C reduction under the efficacy estimand. The trial record lists NCT05929079.
Adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes · Phase 3 · 80 weeks
Lilly reported up to 22.6% mean body-weight reduction in the 12 mg arm under the efficacy estimand. The cardiovascular-event estimates were exploratory and imprecise; detailed results were described as pending future presentation and publication.
Adults with obesity or overweight and knee osteoarthritis, without diabetes · Phase 3 · 68 weeks
Lilly reported 28.7% mean body-weight reduction in the 12 mg arm under the efficacy estimand at 68 weeks. The trial record lists NCT05931367. The detailed peer-reviewed report was not identified as published at this tracker’s review.
How to read this tracker
A full report has passed journal review and exposes methods and analyses for scrutiny.
A primary-source company release is available, but the complete paper may not yet be published.
The registry establishes design and status; it does not substitute for a results publication.